Table 2 Diagnosis and severity of autoimmune hepatitis.
From: Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan
2018 | 2015 | 2015 vs. 2018 | |||
|---|---|---|---|---|---|
Frequency/value | Available no | Frequency/value | Available no | P | |
Diagnosis | |||||
Japanese guide 2013 | |||||
Typical | 80.4% (562) | 699 | – | ||
Atypical | 19.6% (137) | 699 | – | ||
Revised score | – | ||||
Definite | 48.8% (385) | 789 | 48.0% (677) | 1,409 | 0.770 |
Probable | 47.8% (377) | 789 | 48.3% (680) | 1,409 | 0.864 |
Other | 3.4% (27) | 789 | 3.7% (52) | 1,409 | 0.838 |
Simplified score | |||||
Definite | 45.7% (349) | 763 | 38.2% (538) | 1,410 | < 0.001 |
Probable | 31.1% (237) | 763 | 33.6% (476) | 1,410 | 0.219 |
Other | 23.2% (177) | 763 | 28.1% (396) | 1,410 | 0.016 |
Severity | |||||
Mild | 38.5% (297) | 771 | |||
Moderate | 43.6% (336) | 771 | |||
Severe | 17.9% (138) | 771 | |||
(Clinical signs) | |||||
Hepatic encephalopathy | 1.9% (14) | 753 | |||
Reduction or disappearance of hepatic dullness | 2.1% (15) | 710 | |||
(Clinical laboratory tests) | |||||
AST/ALT of more than 200 U/L | 60.9% (480) | 788 | |||
Bilirubin of > 5 mg/dL | 21.6% (170) | 786 | |||
Prothrombin time < 60% | 16.2% (119) | 734 | |||
(Imaging tests) | |||||
Hepatic atrophy | 4.2% (31) | 745 | |||
Heterogeneous liver parenchyma | 11.1% (82) | 740 | |||
